Proteins

DescriptionGS143 is a selective inhibitor of IκBα ubiquitination with IC50 of 5.2 μM for SCFβTrCP1-mediated IκBα ubiquitylation. GS143 suppresses NF-κB activation and transcription of target genes. GS143 exhibits anti-asthma effect.

DescriptionGS143 is a selective inhibitor of IκBα ubiquitination with IC50 of 5.2 μM for SCFβTrCP1-mediated IκBα ubiquitylation. GS143 suppresses NF-κB activation and transcription of target genes. GS143 exhibits anti-asthma effect.

DescriptionGS143 is a selective inhibitor of IκBα ubiquitination with IC50 of 5.2 μM for SCFβTrCP1-mediated IκBα ubiquitylation. GS143 suppresses NF-κB activation and transcription of target genes. GS143 exhibits anti-asthma effect.

Rabbit anti Human GSDMB Antibody, Polyclonal, could be used for WB and so on.ApplicationWB: 1/1000 Protein FunctionThe N-terminal moiety promotes pyroptosis. May be acting by homooligomerizing within the membrane and forming pores

Rabbit anti Human GSDMB Antibody, Polyclonal, could be used for WB and so on.ApplicationWB: 1/1000 Protein FunctionThe N-terminal moiety promotes pyroptosis. May be acting by homooligomerizing within the membrane and forming pores

Rabbit anti Human GSDMB Antibody, Polyclonal, could be used for WB and so on.ApplicationWB: 1/1000 Protein FunctionThe N-terminal moiety promotes pyroptosis. May be acting by homooligomerizing within the membrane and forming pores

Rabbit anti Human GSDMB Antibody, Polyclonal, could be used for WB and so on.ApplicationWB: 1/1000 Protein FunctionThe N-terminal moiety promotes pyroptosis. May be acting by homooligomerizing within the membrane and forming pores

GSK 1070806 (anti-IL-18) is a fully humanized, high-affinity monoclonal antibody targeting IL-18. It has the potential for the treatment of autoinflammatory diseases research, including adult-onset Still’s disease (AOSD).

GSK 1070806 (anti-IL-18) is a fully humanized, high-affinity monoclonal antibody targeting IL-18. It has the potential for the treatment of autoinflammatory diseases research, including adult-onset Still’s disease (AOSD).

GSK 1070806 (anti-IL-18) is a fully humanized, high-affinity monoclonal antibody targeting IL-18. It has the potential for the treatment of autoinflammatory diseases research, including adult-onset Still’s disease (AOSD).

GSK 1070806 (anti-IL-18) is a fully humanized, high-affinity monoclonal antibody targeting IL-18. It has the potential for the treatment of autoinflammatory diseases research, including adult-onset Still’s disease (AOSD).

Potent human fatty acid synthase (hFASN) inhibitor.